Nuvalent
-
Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent, Inc. (NUVL) announced a public offering of 4,950,496 Class A common stock shares at $101.00 per share, anticipating gross proceeds of approximately $500 million. Selling Stockholders granted underwriters an option to purchase up to 742,574 additional shares. J.P. Morgan, Jefferies, TD Cowen, and Cantor are joint book-running managers. The offering is expected to close on November 20, 2025, pending standard conditions. Funds will support Nuvalent’s kinase-driven cancer therapies pipeline. The offering is under a shelf registration statement filed with the SEC.
